StudyFinder
Phase 1, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients with Refractory Locally Advanced or Metastatic Solid Tumors
Status: Recruiting
This study is intended to find the highest amount of the study drug, VT3989, which can be safely taken by patients without causing too many side effects and to determine the recommended dose and dosing schedule for further research, how much of the study drug gets into the blood stream and how long it takes to be cleared, and if the study drug will shrink tumors.
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• metastatic solid tumor or mesothelioma that has progressed on or after all approved therapies of known clinical benefit
• able to walk and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:
• active brain metastases or primary CNS (central nervous system) cancer
• HIV positive or active Hepatitis B or Hepatitis C
• significant heart disease
• another active cancer
• women who are pregnant or breastfeeding
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Mesothelioma, solid tumors
Study Contact: Robert Kratzke - kratz003@umn.edu
Principal Investigator: Robert Kratzke
Phase: PHASE1
IRB Number: STUDY00019430
See this study on ClinicalTrials.gov